---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070280"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T14:32:44.813877+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q1 cash $272.7M; FT819 gets RMAT designation for SLE

## Summary
- Cash, equivalents, and investments $272.7M as of March 31, 2025; projected runway through 1H27.
- FT819 granted RMAT designation by FDA for moderate-to-severe SLE; new data at EULAR June 11.
- Phase 1 study expanded to include AAV, IIM, SSc autoimmune disease cohorts; enrollment ongoing.
- Revenue $1.6M from Ono collaboration; total operating expenses $42.9M (R&D $29.1M, G&A $13.8M).
- Common shares outstanding 114.6M; preferred shares (convertible 5:1) 2.8M; pre-funded warrants 3.9M.

## SEC filing metadata
- accession: 0000950170-25-070280
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017025070280/0000950170-25-070280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017025070280/fate-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070280
- JSON: https://secwatch.observer/filing/0000950170-25-070280.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.